tACS Modulates Speech and Cognitive Impairments in People With PD by Targeting the Medial Frontal Cortex
NCT07240272
·
clinicaltrials.gov ↗
NA
Phase
COMPLETED
Status
28
Enrollment
OTHER
Sponsor class
Conditions
Parkinson Disease
Interventions
OTHER:
6Hz-tACS
OTHER:
Sham-tACS
Sponsor
Ke Dong, MD